Puration Announces Next Iteration of Ongoing CBD Consumer Survey Results


Dallas, TX -- February 5, 2020 -- InvestorsHub NewsWire -- Puration, Inc. (USOTC: PURA) today announced a next iteration of an ongoing CBD consumer survey conducted by Goldman Research on behalf of PURA to gauge and refine the company’s ongoing approach to the CBD consumer market.  This iteration of the survey specifically addressed consumer reaction to recent negative comments from the FDA in regard to CBD.  The survey results indicated that in general, the FDA comments have had little impact on consumer demand and that consumer demand continues to grow.

“As we pursue a strategy to expand our production of CBD infused beverages to include CBD infused edibles and topicals, the CBD survey provides essential feedback,” said PURA CEO Brian Shibley. “This iteration is particularly timely as PURA moves closer to securing a $5 million investment to fund an aggressive acquisition campaign to accelerate our expansion into addition CBD infused consumer products.”

The Goldman CBD consumer survey included a PURA speculative BUY recommendation and at $0.35 target PPS.  PURA closed yesterday at $0.29.  Realizing the target PPS could deliver a 1000% ROI. 

The full CBD consumer survey update can be viewed at GOLDMAN CBD SURVEY

For more information on Puration, visit http://www.purationinc.com

Goldman has aslo recently reviewed Data443 Risk Mitigation, Inc. (ATDS), Alternet Systems, Inc. (ALYI) and Exxe Group (AXXA).

Disclaimer/Safe Harbor: 

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. 

Contact:
Puration, Inc.
Brian Shibley,

info@aciconglomerated.com
(800) 861-1350

 

Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Puration (CE) Charts.
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Puration (CE) Charts.